ArticleJCI insight2016
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia.
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00049517 (A Phase III Trial in Adult Acute Myeloid Leukemia), which is not on this map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Targeting protein tyrosine phosphatase non-receptor type 6 (PTPN6) as a therapeutic strategy in acute myeloid leukemia.Cell biology and toxicology · 2024Article
- High TCTA expression is an adverse prognostic biomarker in acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2024Article
- Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors.Cancers · 2023Review
- Epigenetically programmed resistance to chemo- and immuno-therapies.Advances in cancer research · 2023Article
- Roadmap on plasticity and epigenetics in cancer.Physical biology · 2022Review
- Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML.Cancer discovery · 2020Article
- Lineage tracing of acute myeloid leukemia reveals the impact of hypomethylating agents on chemoresistance selection.Nature communications · 2019Article
- The roles of DNA, RNA and histone methylation in ageing and cancer.Nature reviews. Molecular cell biology · 2019Review
- Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications.International journal of molecular sciences · 2019Review
- A Pilot Study of Aberrant CpG Island Hypermethylation ofInternational journal of medical sciences · 2019Article
- Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.OncoTargets and therapy · 2018Review
- Detection of prognostic methylation markers by methylC-capture sequencing in acute myeloid leukemia.Oncotarget · 2017Article
- Clinical implications of genome-wide DNA methylation studies in acute myeloid leukemia.Journal of hematology & oncology · 2017Review
- Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.American journal of hematology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundVariable response to chemotherapy in acute myeloid leukemia (AML) represents a major treatment challenge. Clinical and genetic features incompletely predict outcome. The value of clinical epigenetic assays for risk classification has not been extensively explored. We assess the prognostic implications of a clinical assay for multilocus DNA methylation on adult patients with de novo AML.
methodsWe performed multilocus DNA methylation assessment using xMELP on samples and calculated a methylation statistic (M-score) for 166 patients from UPENN with de novo AML who received induction chemotherapy. The association of M-score with complete remission (CR) and overall survival (OS) was evaluated. The optimal M-score cut-point for identifying groups with differing survival was used to define a binary M-score classifier. This classifier was validated in an independent cohort of 383 patients from the Eastern Cooperative Oncology Group Trial 1900 (E1900; NCT00049517).
resultsA higher mean M-score was associated with death and failure to achieve CR. Multivariable analysis confirmed that a higher M-score was associated with death (
conclusionThe M-score represents a valid binary prognostic classifier for patients with de novo AML. The xMELP assay and associated M-score can be used for prognosis and should be further investigated for clinical decision making in AML patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.